Journal
EUROPEAN JOURNAL OF CANCER
Volume 44, Issue 12, Pages 1645-1656Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2008.05.015
Keywords
angiogenesis; neuroblastoma; anti-angiogenesis; VEGF; bevacizumab
Categories
Ask authors/readers for more resources
Several research investigations on neuroblastoma (NB) have shown the important dependency of this embryonic tumour on angiogenesis, especially in the advanced and aggressive stages. However, the first pre-clinical data on anti-angiogenic drugs in NB have not been published until recently and clinical trials with anti-angiogenic agents in NB treatment protocols are still missing. Here, we summarise current knowledge on the important role and mechanisms of angiogenesis in NB, and report available pre-clinical results of anti-angiogenic agents used to treat NB. This review clearly shows that angiogenesis is a target in NB and that clinical trials are urgently needed to bring forward promising anti-angiogenesis treatment strategies into NB therapy. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available